Browse investing articles and stock analysis by Jake Lerch. Get expert financial insights and investment advice from The Motley Fool.

Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

Strategic acquisition -- Grupo Aeroportuario del Sureste ( ASR +1.31%) entered a definitive agreement to acquire URW Airports for an enterprise value of $295 million, providing entry into high-traffic ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

gTLD process -- The ICANN 2026 round of new generic Top-Level Domains is intended to start in Q2 2026, with no future ...

Disposition Activity -- Q3 proceeds totaled $19.3 million, with $4.6 million in gains; year-to-date sales reached $133.8 ...

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Both of these electric air taxi pioneers have sold off hard recently, creating a potential entry point for patient investors.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term ...